Company: RENEF
Filing Date: 2025-10-20
Form Type: DEF 14A
Source: 0001104659-25-100857
Chunk: 39

Company: Cartesian Growth Corp II
Filing Date: 2025-10-20
Form: DEF 14A
Chunk 39
---
 to dissent and obtain payment for
their shares.

Shareholder Proposals

In accordance with the Charter,
notice specifying the general nature of the business to be conducted at any general meeting must be given in the notice convening that
meeting.

Other Business

The Board does not know of
any other matters to be presented at the Extraordinary General Meeting. If any additional matters are properly presented at the Extraordinary
General Meeting, the persons named in the enclosed proxy card will have discretion to vote the shares they represent in accordance with
their own judgment on such matters.

Principal Executive Offices

Our principal executive offices
are located at 505 Fifth Avenue, 15th Floor, New York, New York 10017. Our telephone number is (212) 461-6363. Our corporate website
address is https://www.cartesiangrowth.com/cgc2. Our website and the information contained on, or that can be accessed through, the website
is not deemed to be incorporated by reference in, and is not considered part of, this proxy statement.

<div align='center'>19

PROPOSAL NO. 1 — THE EXTENSION PROPOSAL</div>

Background

On May 10, 2022, the Company
consummated an IPO of 23,000,000 units at $10.00 per unit (the “Units” and, with respect to the ordinary shares included
in the Units, the “Public Shares”), including the issuance of 3,000,000 units as a result of the underwriters’ full
exercise of their over-allotment option, at $10.00 per unit, and the sale of 8,900,000 Private Warrants at a price of $1.00 per Private
Warrant in a private placement to the Sponsor that closed simultaneously with the closing of the IPO, generating gross proceeds of $8,900,000
(the “Private Placement”). The Company has listed the Units on the Nasdaq Stock Market LLC (“Nasdaq”). A total
of $236,900,000 ($10.30 per unit) of the net proceeds from the IPO, including the full exercise of the over-allotment option, the sale
of the private placement warrants and the sponsor loan, was placed in the Trust Account. Transaction costs of the IPO amounted to $16,804,728,
consisting of $4,600,000 of underwriting commissions, $11,500,000 of deferred underwriting commissions and $704,